[go: up one dir, main page]

UA81612C2 - Раствор для инъекций, который содержит антагонист lhrh - Google Patents

Раствор для инъекций, который содержит антагонист lhrh

Info

Publication number
UA81612C2
UA81612C2 UA20040503816A UA20040503816A UA81612C2 UA 81612 C2 UA81612 C2 UA 81612C2 UA 20040503816 A UA20040503816 A UA 20040503816A UA 20040503816 A UA20040503816 A UA 20040503816A UA 81612 C2 UA81612 C2 UA 81612C2
Authority
UA
Ukraine
Prior art keywords
lhrh antagonist
injection solution
lhrh
antagonist
cetrorelix
Prior art date
Application number
UA20040503816A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вернер Сарликиотис
Хорст Бауэр
Маттиас Рихер
Юрген Энгел
Франк Гютлайн
Стефано Доминик Ди
Original Assignee
Центарис Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Центарис Гмбх filed Critical Центарис Гмбх
Publication of UA81612C2 publication Critical patent/UA81612C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Водный раствор для инъекций, который содержит антагонист LHRH, содержит кроме антагониста LHRH, такого как цетрореликс, органическую, физиологически приемлемую кислоту и, по желанию, сурфактант, а также общий наполнитель. Антагонист LHRH имеет значительно улучшенную растворимость и может быть получен в более высокой концентрации и с улучшенной биодоступностью. Способность к агрегации антагониста LHRH значительно уменьшена.
UA20040503816A 2001-11-26 2002-11-15 Раствор для инъекций, который содержит антагонист lhrh UA81612C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10157628A DE10157628A1 (de) 2001-11-26 2001-11-26 Injektionslösung eines LHRH-Antagonisten
PCT/EP2002/012798 WO2003045419A1 (de) 2001-11-26 2002-11-15 Injektionslösung eines lhrh-antagonisten

Publications (1)

Publication Number Publication Date
UA81612C2 true UA81612C2 (ru) 2008-01-25

Family

ID=7706799

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040503816A UA81612C2 (ru) 2001-11-26 2002-11-15 Раствор для инъекций, который содержит антагонист lhrh

Country Status (32)

Country Link
EP (1) EP1448221B1 (ru)
JP (1) JP4343693B2 (ru)
KR (1) KR100936636B1 (ru)
CN (1) CN100404068C (ru)
AR (1) AR037424A1 (ru)
AT (1) ATE350050T1 (ru)
AU (1) AU2002365504B2 (ru)
BR (1) BRPI0214412B8 (ru)
CO (1) CO5580793A2 (ru)
CY (1) CY1106401T1 (ru)
DE (2) DE10157628A1 (ru)
DK (1) DK1448221T3 (ru)
EA (1) EA010787B1 (ru)
ES (1) ES2276970T3 (ru)
GE (1) GEP20063861B (ru)
HR (1) HRP20040587B1 (ru)
HU (1) HU230992B1 (ru)
IL (2) IL161894A0 (ru)
IS (1) IS2725B (ru)
ME (1) ME00499B (ru)
MX (1) MXPA04005018A (ru)
NO (1) NO333364B1 (ru)
NZ (1) NZ533712A (ru)
PL (1) PL206199B1 (ru)
PT (1) PT1448221E (ru)
RS (1) RS51408B (ru)
RU (1) RU2322969C2 (ru)
SI (1) SI1448221T1 (ru)
TW (1) TWI312283B (ru)
UA (1) UA81612C2 (ru)
WO (1) WO2003045419A1 (ru)
ZA (1) ZA200404051B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
MX2008012678A (es) 2006-04-07 2008-12-17 Merrion Res Iii Ltd Forma de dosis oral solida que contiene un mejorador.
CA2723541A1 (en) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CN103690560B (zh) * 2013-12-17 2016-08-17 辽宁海思科制药有限公司 一种转化糖电解质注射液药物组合物及其制备方法
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
RU2614234C2 (ru) * 2015-03-31 2017-03-23 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Фармацевтическая композиция на основе 3-(4-Метилимидазол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства
KR20190112029A (ko) * 2017-01-30 2019-10-02 안테브 리미티드 적어도 하나의 gnrh 길항제를 포함하는 조성물
PT3811927T (pt) 2019-10-24 2021-12-14 Sun Pharmaceutical Ind Ltd Forma galénica parentérica estável de acetato de cetrorrelix

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5140009A (en) * 1988-02-10 1992-08-18 Tap Pharmaceuticals, Inc. Octapeptide LHRH antagonists
US5300492A (en) * 1988-02-10 1994-04-05 Tap Pharmaceuticals LHRH analogs
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
HK1049117A1 (zh) * 1999-09-23 2003-05-02 赞塔里斯有限公司 用於治疗子宫内膜组织子宫外增生、慢性骨盆疼痛和输卵管梗助的方法
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung

Also Published As

Publication number Publication date
AR037424A1 (es) 2004-11-10
CO5580793A2 (es) 2005-11-30
EA010787B1 (ru) 2008-10-30
TWI312283B (en) 2009-07-21
JP4343693B2 (ja) 2009-10-14
GEP20063861B (en) 2006-06-26
PT1448221E (pt) 2007-03-30
DK1448221T3 (da) 2007-03-19
DE10157628A1 (de) 2003-06-12
WO2003045419A1 (de) 2003-06-05
TW200300352A (en) 2003-06-01
HK1073078A1 (zh) 2005-09-23
IS7251A (is) 2004-05-06
EA200400742A1 (ru) 2004-12-30
RS51408B (sr) 2011-02-28
IS2725B (is) 2011-03-15
ME00499B (me) 2011-10-10
IL161894A0 (en) 2005-11-20
EP1448221B1 (de) 2007-01-03
NO333364B1 (no) 2013-05-13
CN1592630A (zh) 2005-03-09
KR20040058312A (ko) 2004-07-03
PL206199B1 (pl) 2010-07-30
NO20042449L (no) 2004-06-11
HUP0401986A3 (en) 2012-09-28
RU2004119821A (ru) 2005-04-20
MXPA04005018A (es) 2004-08-11
RU2322969C2 (ru) 2008-04-27
CY1106401T1 (el) 2011-10-12
RS44904A (sr) 2006-10-27
HRP20040587A2 (en) 2004-10-31
NZ533712A (en) 2006-01-27
BRPI0214412B8 (pt) 2021-05-25
BR0214412A (pt) 2004-09-14
BRPI0214412B1 (pt) 2016-01-05
HU230992B1 (hu) 2019-08-28
IL161894A (en) 2014-05-28
AU2002365504A1 (en) 2003-06-10
SI1448221T1 (sl) 2007-06-30
AU2002365504B2 (en) 2007-06-28
HRP20040587B1 (en) 2008-01-31
ES2276970T3 (es) 2007-07-01
PL369548A1 (en) 2005-05-02
CN100404068C (zh) 2008-07-23
KR100936636B1 (ko) 2010-01-14
EP1448221A1 (de) 2004-08-25
ATE350050T1 (de) 2007-01-15
DE50209193D1 (de) 2007-02-15
JP2005510544A (ja) 2005-04-21
HUP0401986A2 (hu) 2005-01-28
ZA200404051B (en) 2005-05-25

Similar Documents

Publication Publication Date Title
Jain et al. Estimation of the aqueous solubility I: application to organic nonelectrolytes
MXPA04005018A (es) Solucion inyectable que comprende un antagonista de lhrh.
TW200628157A (en) Storage stable perfusion solution for dihydropteridinones
MXPA03011480A (es) Una preparacion farmaceutica acuosa de cilostazol para uso parenteral.
DK1317419T3 (da) Cyanophenoxycarboxylsyre-forbindelser og sammensætninger til at levere aktive midler
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
MY130441A (en) Solutions containing epinastin
CA2412759A1 (en) Injectable solution of an lhrh antagonist
PE20011223A1 (es) Composicion farmaceutica que comprende pemetrexed y un antioxidante como monotioglicerol, l-cisteina y acido tioglicolico
UA86007C2 (ru) Средство для стабилизирования биодизельного топлива
IL145187A0 (en) Echinocandin/carbohydrate complexes
DK1171124T4 (da) Anthelmintpræparater
ATE526988T1 (de) Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
MXPA05008403A (es) Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion.
CO5540279A2 (es) Formulacion liofilitada de 2-metil-tieno-benzodiazepina
PL1543826T3 (pl) Stężony wodny roztwór ambroksolu
NZ521533A (en) Veterinary compositions for the treatment of parasitic diseases containing rafoxanide
DE60135845D1 (de) Pralmorelin-haltige nasentropfen-präparate
TW200727900A (en) Aqueous solution preparation containing camptothecins
EP1142878A3 (en) Pharmaceutical compositions comprising moexipril magnesium
MXPA05004842A (es) Formulacion oromucosal y proceso para su preparacion.
WO2000046328A3 (de) Verwendung von phosphonsäure-modifizierten polyacrylaten als sequestriermittel
WO2006002887A8 (en) Aqueous drink solution of indibulin (d-24851) and an organic acid
RU2003112722A (ru) Фармацевтический водный раствор для инъекций
CN107987980A (zh) 一种无磷环保洗衣粉